$ cat ./records/gates-foundation-awards-path-29-3-million-for-polyvalent-group-b--2022.txt
Gates Foundation Awards PATH $29.3 Million for Polyvalent Group B Streptococcus Conjugate Vaccine Development
[RECORD.TXT] · cat --full
As part of its $127.5 million September 2022 maternal vaccine commitment, the Gates Foundation awarded PATH a five-year $29.3 million grant to develop a polyvalent conjugate GBS vaccine protecting against the most common disease-causing serotypes. PATH works with Biovac and developing-country manufacturers to build LMIC production capacity. The grant complements the concurrent $100 million Pfizer Phase 3 manufacturing grant as a two-track strategy ensuring both vaccine innovation and affordable delivery.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Breakthrough Energy Ventures Co-Leads $22 Million Series A for Rondo Energy Industrial Heat Battery
Next →
Gates Foundation Grants Pfizer $100 Million for Group B Streptococcus Maternal Vaccine Phase 3 and LMIC Access
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.